Artiva Biotherapeutics, Inc. Common Stock (ARTV) - Total Liabilities
Based on the latest financial reports, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has total liabilities worth $19.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Artiva Biotherapeutics, Inc. Common Stoc annual equity growth to track the company's year-over-year net asset growth rate.
Artiva Biotherapeutics, Inc. Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Artiva Biotherapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Artiva Biotherapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SG Co. Ltd
KQ:255220
|
Korea | ₩124.11 Billion |
|
Embellence Group AB
ST:EMBELL
|
Sweden | Skr248.00 Million |
|
Alcadon Group AB
ST:ALCA
|
Sweden | Skr737.80 Million |
|
ShareHope Medicine Co Ltd
TWO:8403
|
Taiwan | NT$2.78 Billion |
|
Kothari Petrochemicals Limited
NSE:KOTHARIPET
|
India | Rs695.53 Million |
|
SHEPHERD NEAME P. CONS.
F:43Y
|
Germany | €183.58 Million |
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
China | CN¥5.71 Billion |
|
Tambun Indah Land Bhd
KLSE:5191
|
Malaysia | RM97.03 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Artiva Biotherapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARTV market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Artiva Biotherapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Artiva Biotherapeutics, Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Artiva Biotherapeutics, Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.94 Million | -91.41% |
| 2023-12-31 | $267.13 Million | -2.42% |
| 2022-12-31 | $273.75 Million | +5.78% |
| 2021-12-31 | $258.78 Million | +409.41% |
| 2020-12-31 | $50.80 Million | +477.35% |
| 2019-12-31 | $8.80 Million | -- |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more